2m 2m 2m 2m 2m 2m 2m
- $29.4MMarket Cap
- -31.37%1-Year Change
- BiotechnologyIndustry
DYADIC INTL (DYAI)
Key Performance
More- Earnings Score: N/A
- Momentum Score: 33
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
Dyadic International, Inc. (Nasdaq: DYAI), a biotechnology company specializing in precision-engineered proteins and enzymes, will deliver a live interactive presentation at the Skyline Signature Series on May 27, 2026 at 12:00 PM ET. The event will allow investors to ask questions in real time and requires pre-registration.
05/21/2026, 3:45 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/02/2026
Company Profile
Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd; license agreement with Rubic One Health to develop various livestock vaccines; and sub-license agreement with Phibro Animal Health/Abic Biological Laboratories to develop vaccines and treatments for livestock diseases. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
Key Executives
- Mark A. Emalfarb
- Joseph Hazelton
- Ping Wang Rawson
- Ana Gómez Rodriguez
Current Ownership Distribution
- Institutions85.5M (71.30%)
- Mutual Funds20.9M (17.40%)
- Insiders13.5M (11.30%)
- Other0 (0.00%)